Twitter Facebook LinkedIn YouTube

BioMark Diagnostics (CSE: BUX) New Listing

Video Platform Video Management Video Solutions Video Player

The Canadian-based company is in the process of developing an advanced stage cancer diagnostic business. BioMark’s cancer diagnostics technology, initially licensed from the University of Manitoba, has developed to date into a metabolomics-based diagnostic assay that allows for early cancer detection.

Additional Information:

Company: BioMark Diagnostics
Website: http://www.biomarkdiagnostics.com/
Stock Symbol: CSE: BUX
Date Published: Nov 5, 2014
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

BioMark Diagnostics is one of the latest new listings on the Canadian Securities Exchange, and is trading under the symbol “BUX”.

The Canadian-based company is in the process of developing an advanced stage cancer diagnostic business. BioMark’s cancer diagnostics technology, initially licensed from the University of Manitoba, has developed to date into a metabolomics-based diagnostic assay that allows for early cancer detection.

The company is currently focused on bringing its cancer diagnostic kits and detection system up to commercialization standards and hopes to commence distribution once clinical trials are complete and regulatory acceptance is obtained.

Phase III clinical trials are underway, utilizing a known DNA-approved drug to act as an indicator serving as a biomarker for cancer detection.

The system is non-invasive with high predictability and sensitivity for early detection.

Global markets for cancer diagnostics are set to grow to $5.3 billion annually.

Representatives from the company have joined Richard Carleton, CEO of the Canadian Securities Exchange, and other select companies, on a week-long tour, which started November 5th, visiting Frankfurt, Munich, Zurich and Geneva.

The company currently trades at $0.47, and with 47.3 million shares outstanding, the company is capitalized at $22.2 million.

For more information, please visit the company’s website www.biomarkdiagnostics.com or contact Abdul Mohamed, CFO, at 604-282-6567 or by email info@biomarkdiagnostics.com.
..
I’m Samantha Deutscher for Investmentpitch Media
For more video news, and to view our disclaimer, please visit our website at www.investmentpitch.com and to receive our latest videos, please sign up for our RSS feed.
This video is for information purposes only and it not a recommendation to buy or sell any securities.